Chu Besancon

Besançon 25030

1 studies enrolling now · 4 studies all time

What they study most

Advanced Breast Cancer, Breast Cancer, HER2 Positive Breast Cancer, HER2- Negative Breast Cancer, Hormone Receptor Positive Tumor, Metastatic Breast Cancer, Non-segmental Vitiligo, PIK3CA Mutation, Ulcerative Colitis, Ulcerative Colitis Chronic

Studies at this site

• Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer — Recruiting now
• A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer — Running, not enrolling
• A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis — Completed
• Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2) — Completed